D.A. Davidson & Co. Biomarin Pharmaceutical Inc Transaction History

D.A. Davidson & Co.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 02, 2020	SELL	$71.87 - $131.03 $379,761 - $692,362	-5,284 Closed	0 $0
Q2 2020 Aug 10, 2020	SELL	$79.55 - $124.22 $6,761 - $10,558	-85 Reduced 1.58%	5,284 $652,000
Q1 2020 May 05, 2020	BUY	$71.37 - $96.85 $16,629 - $22,566	233 Added 4.54%	5,369 $454,000
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $127,061 - $170,753	1,977 Added 62.58%	5,136 $434,000
Q3 2019 Nov 05, 2019	BUY	$67.4 - $85.11 $212,916 - $268,862	3,159 New	3,159 $213,000
Q3 2017 Nov 08, 2017	SELL	$80.6 - $94.95 $20,150 - $23,737	-250 Closed	0 $0
Q2 2017 Aug 11, 2017	BUY	N/A	250	250 $0

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.